| Name | Title | Contact Details |
|---|
Kira Pharmaceuticals is pioneering complement drug discovery to deliver transformative therapies for people with complement-mediated diseases
Disc Medicine is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. We are building a portfolio of innovative, first-in-class therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease.
Omicia is unlocking the potential of individualized medicine. Our mission is to help researchers and clinicians understand and apply the most relevant information from personal genome sequences, to improve disease management and medical outcomes. Researchers and clinical diagnostic organizations use our solutions to analyze and identify the genetic basis of a variety of conditions, including childhood disease, cancer and cardiovascular disease. Opal™, the leading platform for fast, accurate and flexible genome analysis, enables clinicians, researchers and bioinformaticians alike to derive clinically relevant insights from genomic data. VAAST, our robust novel disease gene finder and variant scoring algorithm, is in use at more than 300 academic and clinical institutions including the NIH, the University of Oxford, the University of Cambridge, Seattle Children’s Research Institute, Institut Pasteur, University of Maryland Institute for Genome Sciences, and UCSF.
Enthalpy Analytical, Inc. is a Durham, NC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Surrozen is a biotechnology company focused on discovering and developing novel regenerative medicines with a focus on unlocking the powerful self-renewal properties of the body through specific control of the Wnt signaling pathway.